• Dixiang Song, Jianguo Li, Yixuan Zhai, Fengdong Yang, Minkai Wang, Chao Zhao, and Xinting Wei.
• Department of Neurosurgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
• World Neurosurg. 2021 May 1; 149: e63-e70.

BackgroundCarbamazepine (CBZ) is the first-line therapy for trigeminal neuralgia (TN), and microvascular decompression (MVD) is considered to be an effective surgical treatment for TN. However, the effect of preoperative CBZ treatment on MVD outcome is not clear.MethodsFrom 2013 to 2019, 63 patients with classical TN underwent MVD at the First Affiliated Hospital of Zhengzhou University, China. Data were collected through telephone follow-up and electronic medical records in April 2020. Short-term surgical outcome and long-term follow-up data were estimated by univariate and multivariate analysis.ResultsMultivariate analysis indicated that preoperative CBZ treatment was not a significant predictor for short-term outcomes of MVD (P > 0.05). Multivariate analysis for the long-term outcome of MVD indicated that preoperative CBZ treatment could predict postoperative recurrence of TN (P < 0.05).ConclusionsFor patients with classical TN, a longer preoperative medication history of CBZ treatment had no significant effect on short-term outcome of MVD, but CBZ treatment was associated with a poor long-term outcome following MVD.Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

23 keywords...

hide…